Malaysia-based private equity firm Creador announced Monday its investment into La Renon Healthcare by acquiring a 7 percent stake from the promoter and existing investor Peak XV Partners (formerly Sequoia India).

Creador said in a statement that the transaction marks the firm’s continued focus on partnering with high-quality healthcare companies.

The promoter family lead by Pankaj Singh continues to hold a controlling stake in the company.

Founded in 2007, La Renon is a leading player in branded formulation market in India with a strong presence in nephrology, neurology, and other chronic segments.

The company has built a strong reputation for its differentiated product portfolio and has earned deep trust among healthcare professionals through its unwavering focus on clinical excellence and patient-centric approach.

La Renon is among India’s fastest-growing pharmaceutical companies, having delivered a 25 percent of compound annual growth rate (CAGR) in revenue and a 30 percent CAGR in earnings before interest, taxes, depreciation, and amortization (EBITDA) over the last decade.

For FY25, the company reported revenue of INR 1,685 crore ($187 million) and EBITDA of INR 356 crore and is poised to sustain its strong growth momentum and deliver another year of record profitability in FY26.

“Creador’s investment marks a major milestone in the Company’s rapid growth journey and reflects a strong confidence in its performance track record,

“Creador’s deep experience and understanding of the healthcare sector make them an ideal long-term partner for us,” said Pankaj Singh, Founder and Managing Director of La Renon.

“With Creador’s partnership, we aim to continue our accelerated growth path as we shape the next phase of La Renon’s journey towards the top 10 position,” he added.

This investment also underscores Creador’s conviction in the long-term growth potential of India’s healthcare and pharmaceutical sectors.

Peak XV has been invested in La Renon since 2015, with A91 joined in 2021, and ChrysCapital has invested in 2024.

La Renon onboarded other marquee investors namely Avendus, WhiteOak and Sigular Guff in 2025.

Citadel Management Consulting acted as the exclusive financial advisor to La Renon on this transaction.

“This investment from Creador is yet another massive validation of La Renon’s strong positioning in Chronic Therapies,” said Vijay Datt, Chief Executive Officer of Citadel.

Malaysia’s PE firm Creador closes Fund VI at $930 million, says Founder & CEO Brahmal Vasudevan